Improving the translation of animal ischemic stroke studies to humans

Glen C. Jickling, Frank R Sharp

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Despite testing more than 1,026 therapeutic strategies in models of ischemic stroke and 114 therapies in human ischemic stroke, only one agent tissue plasminogen activator has successfully been translated to clinical practice as a treatment for acute stroke. Though disappointing, this immense body of work has led to a rethinking of animal stroke models and how to better translate therapies to patients with ischemic stroke. Several recommendations have been made, including the STAIR recommendations and statements of RIGOR from the NIH/NINDS. In this commentary we discuss additional aspects that may be important to improve the translational success of ischemic stroke therapies. These include use of tissue plasminogen activator in animal studies; modeling ischemic stroke heterogeneity in terms of infarct size and cause of human stroke; addressing the confounding effect of anesthesia; use of comparable therapeutic dosage between humans and animals based on biological effect; modeling the human immune system; and developing outcome measures in animals comparable to those used in human stroke trials. With additional study and improved animal modeling of factors involved in human ischemic stroke, we are optimistic that new stroke therapies will be developed.

Original languageEnglish (US)
Pages (from-to)1-7
Number of pages7
JournalMetabolic Brain Disease
DOIs
StateAccepted/In press - 2014

Fingerprint

Animals
Stroke
Tissue Plasminogen Activator
Immune system
Therapeutics
National Institute of Neurological Disorders and Stroke
Testing
Therapeutic Uses
Immune System
Anesthesia
Animal Models
Outcome Assessment (Health Care)

Keywords

  • Animal models
  • Cerebrovascular disease
  • Clinical trial
  • Stroke

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience
  • Clinical Neurology
  • Biochemistry

Cite this

Improving the translation of animal ischemic stroke studies to humans. / Jickling, Glen C.; Sharp, Frank R.

In: Metabolic Brain Disease, 2014, p. 1-7.

Research output: Contribution to journalArticle

@article{646bdede0218419a8ab5ec9eb129e34d,
title = "Improving the translation of animal ischemic stroke studies to humans",
abstract = "Despite testing more than 1,026 therapeutic strategies in models of ischemic stroke and 114 therapies in human ischemic stroke, only one agent tissue plasminogen activator has successfully been translated to clinical practice as a treatment for acute stroke. Though disappointing, this immense body of work has led to a rethinking of animal stroke models and how to better translate therapies to patients with ischemic stroke. Several recommendations have been made, including the STAIR recommendations and statements of RIGOR from the NIH/NINDS. In this commentary we discuss additional aspects that may be important to improve the translational success of ischemic stroke therapies. These include use of tissue plasminogen activator in animal studies; modeling ischemic stroke heterogeneity in terms of infarct size and cause of human stroke; addressing the confounding effect of anesthesia; use of comparable therapeutic dosage between humans and animals based on biological effect; modeling the human immune system; and developing outcome measures in animals comparable to those used in human stroke trials. With additional study and improved animal modeling of factors involved in human ischemic stroke, we are optimistic that new stroke therapies will be developed.",
keywords = "Animal models, Cerebrovascular disease, Clinical trial, Stroke",
author = "Jickling, {Glen C.} and Sharp, {Frank R}",
year = "2014",
doi = "10.1007/s11011-014-9499-2",
language = "English (US)",
pages = "1--7",
journal = "Metabolic Brain Disease",
issn = "0885-7490",
publisher = "Springer New York",

}

TY - JOUR

T1 - Improving the translation of animal ischemic stroke studies to humans

AU - Jickling, Glen C.

AU - Sharp, Frank R

PY - 2014

Y1 - 2014

N2 - Despite testing more than 1,026 therapeutic strategies in models of ischemic stroke and 114 therapies in human ischemic stroke, only one agent tissue plasminogen activator has successfully been translated to clinical practice as a treatment for acute stroke. Though disappointing, this immense body of work has led to a rethinking of animal stroke models and how to better translate therapies to patients with ischemic stroke. Several recommendations have been made, including the STAIR recommendations and statements of RIGOR from the NIH/NINDS. In this commentary we discuss additional aspects that may be important to improve the translational success of ischemic stroke therapies. These include use of tissue plasminogen activator in animal studies; modeling ischemic stroke heterogeneity in terms of infarct size and cause of human stroke; addressing the confounding effect of anesthesia; use of comparable therapeutic dosage between humans and animals based on biological effect; modeling the human immune system; and developing outcome measures in animals comparable to those used in human stroke trials. With additional study and improved animal modeling of factors involved in human ischemic stroke, we are optimistic that new stroke therapies will be developed.

AB - Despite testing more than 1,026 therapeutic strategies in models of ischemic stroke and 114 therapies in human ischemic stroke, only one agent tissue plasminogen activator has successfully been translated to clinical practice as a treatment for acute stroke. Though disappointing, this immense body of work has led to a rethinking of animal stroke models and how to better translate therapies to patients with ischemic stroke. Several recommendations have been made, including the STAIR recommendations and statements of RIGOR from the NIH/NINDS. In this commentary we discuss additional aspects that may be important to improve the translational success of ischemic stroke therapies. These include use of tissue plasminogen activator in animal studies; modeling ischemic stroke heterogeneity in terms of infarct size and cause of human stroke; addressing the confounding effect of anesthesia; use of comparable therapeutic dosage between humans and animals based on biological effect; modeling the human immune system; and developing outcome measures in animals comparable to those used in human stroke trials. With additional study and improved animal modeling of factors involved in human ischemic stroke, we are optimistic that new stroke therapies will be developed.

KW - Animal models

KW - Cerebrovascular disease

KW - Clinical trial

KW - Stroke

UR - http://www.scopus.com/inward/record.url?scp=84893700628&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893700628&partnerID=8YFLogxK

U2 - 10.1007/s11011-014-9499-2

DO - 10.1007/s11011-014-9499-2

M3 - Article

C2 - 24526567

AN - SCOPUS:84893700628

SP - 1

EP - 7

JO - Metabolic Brain Disease

JF - Metabolic Brain Disease

SN - 0885-7490

ER -